Skip to content

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

Late-Onset Neonatal Sepsis | Extreme Prematurity | Neonatal Hypotension

Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring \>48 hours of age). In Canada, \~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \~35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices.

Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS.

Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS.

Hypothesis: Primary treatment with NE will be associated with a lower mortality

Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 15 centers in Canada, 4 centers in Ireland, 2 centers in Israel and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved:

Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response

Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    21 to 32

Participation Criteria

Inclusion Criteria:

* ≤32 weeks gestational age and \> 48 hours of life
* Receiving primary vasopressor therapy with Dopamine or Norepinephrine in the context of suspected late-onset sepsis or necrotizing enterocolitis with systemic hypotension (defined as: culture positive or negative bloodstream infection)

Exclusion Criteria:

* Known chromosomal or genetic anomalies
* Receiving primary therapy with agents other than Dopamine or Norepinephrine

Study Location

St.Boniface Hospital
St.Boniface Hospital
Winnipeg, Manitoba
Canada

Contact Study Team

Primary Contact

Yasser ElSayed

London Health Sciences Centre
London Health Sciences Centre
London, Ontario
Canada

Contact Study Team

Primary Contact

Soume Bhattacharya

Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Stephanie Fevrier, MSc

[email protected]
Montreal Children's Hospital
Montreal Children's Hospital
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Gabriel Altit

BC Women's Hospital
BC Women's Hospital
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Michael Castaldo

McMaster Children's Hospital
McMaster Children's Hospital
Hamilton, Ontario
Canada

Contact Study Team

Primary Contact

Amneet Sidhu

Mount Sinai Hospital
Mount Sinai Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Laura Thomas, MSc

[email protected]
Jewish General Hospital
Jewish General Hospital
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Nina Nouraeyan

Winnipeg Health Sciences Centre
Winnipeg Health Sciences Centre
Winnipeg, Manitoba
Canada

Contact Study Team

Primary Contact

Deepak Louis

Children's Hospital of Eastern Ontario
Children's Hospital of Eastern Ontario
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Laurent Renesme

Windsor Regional Hospital
Windsor Regional Hospital
Windsor, Ontario
Canada

Contact Study Team

Primary Contact

Sajit Augustine

Foothill's Medical Centre
Foothill's Medical Centre
Calgary, Alberta
Canada

Contact Study Team

IWK Health Centre
IWK Health Centre
Halifax, Nova Scotia
Canada

Contact Study Team

Hospital for Sick Children
Hospital for Sick Children
Toronto, Ontario
Canada

Contact Study Team

CHU Sainte- Justine
CHU Sainte- Justine
Montréal, Quebec
Canada

Contact Study Team

Study Sponsored By
Mount Sinai Hospital, Canada
Participants Required
More Information
Study ID: NCT05347238